Thus, although P-gp appears to often be the dominant ABC transporter at the blood-brain barrier, these data suggest that dual P-gp/ABCG2 inhibitors may have even greater therapeutic promise for brain diseases[23,84-86]. This evidence concerns the gene ABCG2 and brain disorder.